Status:
UNKNOWN
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Lead Sponsor:
Xiaorong Dong
Conditions:
NSCLC
Anlotinib
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Eligibility Criteria
Inclusion
- The subjects volunteered to join the study and signed the informed consent form. They had good compliance and cooperated with the follow-up;
- Patients between 18-75 years old;
- Extensive small cell lung cancer confirmed by histopathology (according to Veterans Administration lung study group, Valg stage) and did not progress after 4-6 cycles (21 days as a cycle) of first-line standard chemotherapy platinum combined with etoposide \[complete remission (CR), partial remission (PR) or stable (SD) according to recist1.1 standard\];
- The time interval between the first TRT and the end of the last chemotherapy should be less than or equal to 6 weeks;
- The life expectancy shall be at least 3 months;
- ECoG score: 0-1
Exclusion
- Small cell lung cancer patients with other pathological types of tumor species;
- Patients with pathological fracture in bone metastasis of small cell lung cancer;
- Patients with central nervous system metastasis;
- Patients who have received chest radiotherapy before;
- Patients who have used vasotargeted drugs (such as bevacizumab, sunitinib, etc.) including enrotinib and immunosuppressive agents before;
- Imaging (CT or MRI) showed that the distance between the tumor focus and the large blood vessel was less than or equal to 5 mm, or there was a central tumor invading the local large blood vessel, or there was an obvious cavitary or necrotic tumor in the lung;
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04313660
Start Date
April 1 2020
End Date
February 1 2022
Last Update
March 18 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.